ZyVet Animal Health Inc.

What ZyVet Animal Health Inc. does

ZyVet Animal Health Inc. is a U.S. animal health pharmaceutical company that develops, manufactures, and distributes FDA-approved generic drugs for companion animals (dogs and cats). Founded in 2019 and headquartered in Pennington, New Jersey, the company operates as a wholly-owned subsidiary of Zydus Lifesciences Ltd., an Indian multinational pharmaceutical group, and leverages Zydus's 70 years of human generic pharmaceutical experience together with a dedicated USFDA-inspected manufacturing facility.

The company's portfolio consists of ten generic pharmaceutical products spanning major therapeutic categories used in veterinary practice: NSAIDs (Carprofen, Robenacoxib), antibiotics (Enrofloxacin, Marbofloxacin), sedatives (Acepromazine), diuretics (Furosemide), antiemetics (Maropitant), parasiticides (Selamectin), urinary incontinence therapy (Phenylpropanolamine), and anti-inflammatory/antipruritic combinations (Trimeprazine with Prednisolone). All products are positioned as bioequivalent to pioneer (brand-name) drugs, manufactured under USFDA-inspected quality systems, with the company emphasizing packaging and delivery formats that mirror the look and feel of the pioneer products. The first ANADA approval was received in 2023, and the portfolio has since scaled to ten SKUs by 2025.

ZyVet's business model is asset-light commercially: it does not sell directly to veterinarians, animal hospitals, or clinics. Instead, products flow exclusively through authorized veterinary distributors (including Covetrus, Patterson Vet, Midwest Vet Supply, Penn Vet, Cardinal Health, and others), with end customers being licensed veterinarians who dispense medication to pet owners. Pricing is set by distributors and pharmacies rather than by ZyVet. Revenue is not publicly disclosed, and the U.S. is the only served market, with international geographies explicitly out of scope.

Name

ZyVet Animal Health Inc.

Legal name

ZyVet Animal Health Inc.

Website

https://zyvetusa.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

ZyVet Animal Health Inc., a U.S. subsidiary of India's Zydus Lifesciences, develops and manufactures FDA-approved generic pharmaceuticals for companion animals (dogs and cats) and distributes them exclusively through authorized veterinary wholesalers across the United States.

Ownership category

akta.pro rank

Product category

Veterinary Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic & Private-Label Veterinary Pharmaceuticals (HLAMAEAM)

akta.pro secondary industries

Companion Animal Therapeutics (Rx) (HLAMAEAA), Antimicrobials & Anti-infectives (HLAMAEAE), Pain Management, Anesthesia & Critical Care Drugs (HLAMAEAF)

Keywords

• Generic veterinary pharmaceuticals
• Companion animal medications
• FDA-approved animal drugs
• Veterinary product distribution
• Animal health generics

Headquarters

HQ city

Pennington

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Technology or R&D, Personnel, Marketing or Sales

Revenue model

1. Generic Animal Health Pharmaceuticals: Revenue generated from the sale of FDA-approved generic animal health pharmaceutical products distributed through authorized animal health distributors. Products include various tablet and topical formulations for companion animals (dogs and cats).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

ZyVet Animal Health Inc. develops, manufactures, and sells FDA-approved generic prescription pharmaceuticals for companion animals (dogs and cats). Its product portfolio spans NSAIDs, antibiotics, antiemetics, diuretics, sedatives, and parasiticides, distributed exclusively through authorized veterinary distributors across the United States.

Product overview

ZyVet Animal Health is an emerging leader in animal health solutions, offering an ever-growing portfolio of FDA-approved generic pharmaceuticals for companion animals. The company's products are bioequivalent to pioneer drugs and include: Acepromazine Maleate Tablets (sedative/preanesthetic for dogs), Carprofen Chewable Tablets (NSAID for pain/inflammation in dogs), Enrofloxacin Flavored Antibacterial Tablets (broad-spectrum antibiotic for dogs and cats), Furosemide Tablets (diuretic for dogs and cats), Marbofloxacin Tablets (antibiotic for dogs and cats), Maropitant Citrate Tablets (antiemetic for dogs), Phenylpropanolamine Hydrochloride Chewable Tablets (urinary incontinence treatment for dogs), Robenacoxib Tablets (NSAID for cats), Selamectin Topical Solution (topical parasiticide for dogs and cats), and Trimeprazine with Prednisolone Tablets (antipruritic/antitussive for dogs). All products are available through major veterinary distributors across the U.S. and are backed by Zydus Lifesciences' 70 years of human generic pharmaceutical experience.

Differentiator

Problem solved

Functional benefit

Products and services

• Carprofen Chewable Tablets
• Enrofloxacin Tablets
• Maropitant Citrate Injection
• Furosemide Tablets
• Dexmedetomidine Hydrochloride Injection
• Ivermectin and Pyrantel Chewable Tablets
• Cephalexin Capsules
• Meloxicam Oral Suspension
• Fluralaner Chewable Tablets
• Piroxicam Tablets

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Zydus Lifesciences Ltd.coreStrategic or Co-development PartnerZyVet is proud to extend the reach of Zydus Lifesciences Ltd. to the U.S. animal health industry. ZyVet is backed by Zydus's 70 years of human generic pharmaceutical experience and utilizes Zydus's state-of-the-art research and development facilities, including a dedicated animal health manufacturing facility. This partnership enables ZyVet to bring exceptional quality and integrity to the animal health space with pharmaceutical solutions tailored to the U.S. market needs.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Others

• Covetrus: Major veterinary distribution and practice solutions provider that serves as one of ZyVet's primary distribution channels. Comparable as the channel infrastructure through which ZyVet reaches veterinary clinics, and a key commercial partner rather than direct competitor.
• Patterson Veterinary: One of the largest U.S. veterinary distributors supplying companion-animal practices with pharmaceuticals, equipment, and supplies. Comparable as an authorized distributor of ZyVet products and a critical go-to-market channel for the company's generic portfolio.

Broad incumbents

• Elanco Animal Health: Major global animal health company with companion-animal and livestock pharmaceutical brands across parasiticides, pain management, and anti-infectives. Comparable as a broad incumbent whose branded therapies face generic competition from ZyVet-style manufacturers.
• Zoetis: The world's largest animal health company, offering a broad portfolio of branded pharmaceuticals, vaccines, diagnostics, and parasiticides across species. A broad incumbent competitor whose branded products ZyVet directly targets with cheaper bioequivalent generics.
• Merck Animal Health: Division of Merck & Co. offering vaccines, parasiticides, and pharmaceuticals for companion and production animals. Comparable as a broad incumbent whose branded veterinary pharmaceuticals face generic substitution by ZyVet-style generic entrants.

Direct peers

• Norbrook Laboratories: Veterinary pharmaceutical manufacturer specializing in generic and proprietary animal health medicines across companion and livestock species. Closely comparable to ZyVet because Norbrook sells FDA-style approved generic vet drugs through distributor channels into the U.S. and other markets.
• Vetoquinol: Global veterinary pharmaceutical company with a sizable generic and specialty generics portfolio for companion and production animals. Directly comparable to ZyVet because both manufacture FDA-style approved generic vet medicines and sell via distributor networks to U.S. veterinary clinics.
• Dechra Pharmaceuticals: Specialty veterinary pharmaceuticals company (now part of EQT) with a strong companion-animal portfolio spanning endocrine, dermatology, and pain management. Comparable to ZyVet in targeting companion-animal therapeutics categories with Rx pharmaceuticals distributed through vet channels.
• Bimeda Animal Health: Global veterinary pharmaceutical company producing generic and branded animal health medicines, including anti-infectives, anti-parasitics, and reproduction products. Directly comparable to ZyVet as a generic-focused vet pharma manufacturer distributing through vet wholesalers.
• Chanelle Pharma: Generic veterinary pharmaceutical manufacturer with a large generic animal health portfolio across therapeutics categories. Closely comparable to ZyVet because Chanelle pursues ANADA-style generic approvals and supplies companion-animal generics to veterinary channels globally.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/zyvet-animal-health-inc

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ZyVet Animal Health Inc.